會議議程
講者簡介
2022/8/13 08:30~11:50 Room B Hall (第二會議室) 1F
- Symposium (2) 自律神經暨暈眩、失智、頭痛
Update in Neurology
- Time
- Topic
- Speaker
- Moderator
- 10:20~10:50
- Glymphatic activities mediate amyloid and tau effect on cognition in patients with AD
- Speaker:
徐榮隆
- Moderator:
王培寧
- Dr 徐榮隆
- MD, PhD
-
主任
新北市立土城醫院
E-mail：tulu@ms36.hinet.net
Executive Summary：
Dr Jung-Lung, Hsu now served as an Chief Neurologist at New Taipei Municipal TuCheng Hospital. He graduated from Taipei Medical University, and received his neurological residency training in Shin Kong WHS Memorial Hospital. He maintained a teaching position at Graduate Institute of Humanities in Medicine, Taipei Medical University as an associate professor. Dr Hsu’s main clinical and academic interests include dementia and neuroimaging. He focuses on application of state-of art neuroimaging technique to answer the clinical questions in dementia field. In 2004 he worked as a visiting fellow in Swartz Center in Computational Neuroscience, University of California, San Diego. He received his PhD degree in 2013 at Image Science Institute, Utrecht University (Netherlands). He participated in the founding of Taiwan Dementia Society, and is the Member of a council of Taiwan Dementia Society (TDS). He has multiple publications on neuroimaging topics and reviewed articles for some international journals.
Dr Jung-Lung, Hsu now served as an Chief Neurologist at New Taipei Municipal TuCheng Hospital. He graduated from Taipei Medical University, and received his neurological residency training in Shin Kong WHS Memorial Hospital. He maintained a teaching position at Graduate Institute of Humanities in Medicine, Taipei Medical University as an associate professor. Dr Hsu’s main clinical and academic interests include dementia and neuroimaging. He focuses on application of state-of art neuroimaging technique to answer the clinical questions in dementia field. In 2004 he worked as a visiting fellow in Swartz Center in Computational Neuroscience, University of California, San Diego. He received his PhD degree in 2013 at Image Science Institute, Utrecht University (Netherlands). He participated in the founding of Taiwan Dementia Society, and is the Member of a council of Taiwan Dementia Society (TDS). He has multiple publications on neuroimaging topics and reviewed articles for some international journals.
Lecture Abstract：
Glymphatic system is a novel clearance mechanism in brain which is responsible for the cerebrospinal fluid (CSF) flow into the brain parenchyma along arterial perivascular space and subsequently into the brain interstitial space which facilitated by the highly polarization of aquaporin 4 (AQP4) water channels on astrocyte, then directs flow forward to venous perivascular space ultimately clearing solutes from the neuropil into meningeal and cervical lymphatic drainage vessels(1). In animal studies, Iliff et al. and other researchers had found that glymphatic system contributes to 55-65% clearance of β-amyloid protein from the mice brain(2, 3). Recently, Harrison et al. showed that glymphatic clearance related to cortical tau deposition in mouse model of tauopathy(4). The dysfunction of glymphatic system had also been proposed as the final common pathway for Alzheimer’s disease (AD) and other primary neurodegenerative disease(5). Despite that substantial knowledge regarding glymphatic system had been gained from animal studies, further study is needed to confirm if these findings could be applied to humans. Recently developed amyloid and tau position emission tomography (PET) image and DTI-ALPS method provide us an opportunity to explore the association between glymphatic activity and amyloid, tau deposition in patients with AD. Our hypothesis is glymphatic activity could be a mediator between amyloid and tau deposition on cognitive dysfunction in patients with AD.
Glymphatic system is a novel clearance mechanism in brain which is responsible for the cerebrospinal fluid (CSF) flow into the brain parenchyma along arterial perivascular space and subsequently into the brain interstitial space which facilitated by the highly polarization of aquaporin 4 (AQP4) water channels on astrocyte, then directs flow forward to venous perivascular space ultimately clearing solutes from the neuropil into meningeal and cervical lymphatic drainage vessels(1). In animal studies, Iliff et al. and other researchers had found that glymphatic system contributes to 55-65% clearance of β-amyloid protein from the mice brain(2, 3). Recently, Harrison et al. showed that glymphatic clearance related to cortical tau deposition in mouse model of tauopathy(4). The dysfunction of glymphatic system had also been proposed as the final common pathway for Alzheimer’s disease (AD) and other primary neurodegenerative disease(5). Despite that substantial knowledge regarding glymphatic system had been gained from animal studies, further study is needed to confirm if these findings could be applied to humans. Recently developed amyloid and tau position emission tomography (PET) image and DTI-ALPS method provide us an opportunity to explore the association between glymphatic activity and amyloid, tau deposition in patients with AD. Our hypothesis is glymphatic activity could be a mediator between amyloid and tau deposition on cognitive dysfunction in patients with AD.